Epizyme entered into a definitive merger agreement with Europe-based Ipsen ( IPSEY - Free Report ) in June, wherein the latter will acquire all the outstanding shares for an estimated aggregate consideration of $247 million. The transaction is expected to be completed by third-quarter 2022.